Whatever the outcome, Zacks Investment Management chief market strategist Brian Mulberry sees a wounded Novo fighting however it can: I understand that [Novo] feels left behind, but this lawsuit is not around any issues with product or performance just accusing [Lilly] of false advertising because their product works too good!?! he wrote
It is not intended for human or veterinary use, and must not be used for diagnostic, therapeutic, or clinical purposes
Curious to hear colleagues thoughts: Will obesity management evolve toward personalized maintenance strategies, or should we aim to keep most patients on optimized therapeutic doses indefinitely
For example: In the SURMOUNT-1 trial, participants taking tirzepatide lost up to 22.5% of body weight over 72 weeks
She took the time to clearly explain all of my options, placement details, and what results to expect
The face does not lose muscle in the same way the body does